

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

## Solid-Supported Oligonucleotide Systems for Special Biomedical Applications

Hartmut Seliger<sup>a</sup>; Michael Hinz<sup>a</sup>; Sigalit Gura<sup>b</sup>; Boa Nitzan<sup>b</sup>; Shlomo Margel<sup>b</sup>

<sup>a</sup> Universität Ulm, Ulm, Germany <sup>b</sup> Department of Chemistry, Bar-Ilan University, Ramat Gan, Israel

**To cite this Article** Seliger, Hartmut , Hinz, Michael , Gura, Sigalit , Nitzan, Boa and Margel, Shlomo(1999) 'Solid-Supported Oligonucleotide Systems for Special Biomedical Applications', *Nucleosides, Nucleotides and Nucleic Acids*, 18: 6, 1305 — 1307

**To link to this Article:** DOI: 10.1080/07328319908044698

**URL:** <http://dx.doi.org/10.1080/07328319908044698>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## SOLID-SUPPORTED OLIGONUCLEOTIDE SYSTEMS FOR SPECIAL BIOMEDICAL APPLICATIONS

Hartmut Seliger, Michael Hinz, Sigalit Gura\*, Boa Nitzan\* and Shlomo Margel\*

Universität Ulm, Sektion Polymere, Albert-Einstein-Allee 11, D 89079 Ulm, Germany,  
and \*Bar-Ilan University, Department of Chemistry, Ramat Gan, 52900 Israel

**ABSTRACT:** The use of composite beads consisting of a 6  $\mu\text{m}$  polystyrene core with 30 nm surface-bound silica particles to routine automatic oligodeoxynucleotide (ODN) synthesis is described.

### INTRODUCTION

For routine oligonucleotide preparations macroporous supports are preferred, since they show maximum accessibility of the growing nucleotide chains to low molecular reagents and solvents. However, if there is an additional demand for the use of macromolecular reactants, e.g. enzymes, a porous matrix may cause diffusion and/or steric hindrance. Such a demand is best fulfilled by supports with an unreactive core and a functionalized outer shell<sup>1</sup>. As a further example, we describe here a composite bead system consisting of an unreactive 6  $\mu\text{m}$  polystyrene core derivatized on the surface with silica microbeads of 30 nm average diameter<sup>2</sup> (Support I, Fig. 1) with respect to its application to routine ODN synthesis. These beads have also been particularly suitable for loading with an extremely small number of DNA molecules for the development of exonucleolytic sequencing<sup>3</sup>.




Fig. 1: Schematic drawing of a core-shell bead




Fig. 2: CE analysis of 40mer

Table 1:

	<i>Support</i>	<i>average yield</i>	<i>total</i>
		<i>%</i>	<i>yield %</i>
40 bases	I	99.1	69.4
40 bases	CPG 1000	98.0	46.1
II, 100 bases	I	99.7	76.5
II, 100 bases	CPG 1000	99.1	39.7
III, 100 bases	I	98.8	30.0
III, 100 bases	CPG 1000	98.9	34.9

## EXPERIMENTS, RESULTS AND DISCUSSION

NH<sub>2</sub>-functionalized composite beads<sup>2</sup> were loaded<sup>4</sup> with 10-27  $\mu$ mol nucleoside/g. Standard ODN synthesis was done on a 0.2  $\mu$ mol routine (synthesizer: Pharmacia 4-primers) with conventional workup. Composite beads with 19  $\mu$ mol nucleoside/g were selected for the preparation of medium to long oligonucleotides. A 40mer sequence was synthesized in 99.1% average elongation yield. The separation of the crude solid-phase product by capillary electrophoresis is shown in Fig. 2. Two 100mers (II and III) were prepared similarly and the correct sequence verified by the Sanger technique (Table 1).

These results show, that support I, although functionalized only within its shell, has similar capacity and similar, if not superior, efficiency, compared to CPG.

#### Acknowledgements

Financial support by the German-Israeli Research Foundation and by the Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie are gratefully acknowledged. These studies were partially supported by Minerva (Otto Meyerhoff Center for the Study of Drug – Receptor Interactions).

#### REFERENCES

1. H. Seliger, R. Bader, E. Birch-Hirschfeld, Z. Földes-Papp, K.H. Gührs, M. Hinz, R. Rösch and C. Scharpf, *Reactive and Functional Polymers*, **1995**, 26, 119-126
2. S. Margel, S. Gura, H. Bamnolker, B. Nitzan, T. Tennenbaum, B. Bar-Toov, M. Hinz, and H. Seliger in: "New Solid and Hollow Magnetic and Non-Magnetic, Organic-Inorganic Hybrid Microspheres: Synthesis, Characterization and Use" in "Scientific and Clinical Applications of Magnetic Carriers", U. Haefeli & W. Schutt (ed.), Plenum Press (**1997**)
3. K. Dörre et al., *Bioimaging*, **1997**, 5, 139-152
4. B.S. Sproat, M.J. Gait, in: *Oligonucleotide Synthesis, a Practical Approach*, M.J. Gait (ed.), IRL Press, Oxford, (**1984**), 83-115